Dr. Woody Emlen is a graduate of Stanford University and the University of California (San Diego) School of Medicine. He was Professor of Medicine and Immunology at the University of Washington and the University of Colorado Health Sciences Center for almost 20 years, where his practice was in Internal Medicine and Rheumatology (Arthritis) and his research focused on inflammatory and autoimmune diseases. In the late 1990s, Dr. Emlen left academic medicine to pursue a career in biotechnology, serving as Vice President of Scientific Affairs for Palo Alto-based InterMune Pharmaceuticals. In 2004 he co-founded his own Denver-based biotechnology company, Taligen Therapeutics, serving as CEO until the Company’s acquisition in 2011. He currently is retired from medicine but serves on the Boards of several early-stage Biotechnology companies.